Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years.
Future Oncol
; 17(20): 2581-2592, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-33764155
ABSTRACT
Aim:
To analyze therapy for metastatic triple-negative breast cancer (mTNBC), factors contributing to survival and costs. Patients &methods:
Using 2010-2016 SEER-Medicare data, we identified women (≥65 years) with mTNBC.Results:
Of 302 eligible patients, 152 (50%) received systemic therapy. In multivariable regression analyses, only age <75 years was associated with therapy receipt (odds ratio 2.91; 95% CI 1.79-4.74); and only systemic therapy significantly reduced risk of death (hazard ratio 0.34; 95% CI 0.26-0.44). Median overall survival was 13.4 (95% CI 11.3-15.1) vs 3.3 months (95% CI 2.7-3.9) in therapy vs no-therapy cohorts. Mean per-patient-per-month costs <30 days before end-of-life/follow-up were $14,100 and $15,600 (2019 USD), respectively.Conclusion:
Poor outcomes and high costs indicate need for more effective mTNBC therapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Assistência Terminal
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Custos de Medicamentos
/
Neoplasias da Mama Masculina
/
Neoplasias de Mama Triplo Negativas
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article